Literature DB >> 10539869

Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease.

S Gupta1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10539869     DOI: 10.1016/s0002-8703(99)70296-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  4 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response.

Authors:  Justin F Deniset; Paul K M Cheung; Elena Dibrov; Kaitlin Lee; Sarah Steigerwald; Grant N Pierce
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

4.  An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention.

Authors:  Woo Kon Jeong; Myung Ho Jeong; Kye Hun Kim; Sang Rok Lee; Ok Young Park; Ju Hyup Yum; Joo Han Kim; Won Kim; Jae Young Rhew; Youn Keun Ahn; Jeong Gwan Cho; Byoung Hee Ahn; Soon Pal Suh; Jong Chun Park; Sang Hyung Kim; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2003-09       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.